Umbilical Cord Tissue Allografts for Cervical Paraspinal Defects
Cervical paraspinal degeneration, marked by fatty infiltration of the paraspinal musculature and enthesopathy at tendon and ligament attachment sites, is a recognized contributor to chronic neck pain. This multi-site observational study, published in Medical Research Archives (2026, 14(6)), evaluated cryopreserved human umbilical cord tissue (UCT) allografts in 31 patients with cervical paraspinal muscle and enthesis defects refractory to standard conservative care.
Study Overview
- Design: IRB-approved multi-site observational study (IRCM-2022-311)
- Participants: 31 patients with MRI- or ultrasound-confirmed cervical paraspinal degeneration refractory to at least 3 months of standard conservative care
- Intervention: Ultrasound-guided application of 2 cc (150 mg) cryopreserved UCT allograft to degeneration sites spanning C1 to C7, delivered as single (n=15), double (n=9), or triple (n=7) application cohorts
- Outcomes: NPRS, WOMAC (Pain, Stiffness, Physical Function, Total), and QOLS at baseline through patient-specific endpoint (90 to 180 days)
Results
Patient-reported improvement (baseline to endpoint):
- Single application: 13 of 15 patients (87%) reported WOMAC Total improvement
- Double application: 7 of 9 patients (78%) reported WOMAC Total improvement
- Triple application: 7 of 7 patients (100%) reported WOMAC Total improvement
Mean change from baseline:
- NPRS: 5.20 → 4.13 (single), 6.00 → 3.11 (double), 7.00 → 1.86 (triple)
- Average percentage improvement reported by the authors, NPRS: 20.67% (single), 58.33% (double), 79.59% (triple); WOMAC Total: 42.62%, 37.93%, 68.70%
- Within-group effect sizes at the triple-application endpoint were large across all six measures (r = 0.58 to 0.81, all p < 0.001)
Between-group post-hoc analysis (Mann-Whitney U) found triple-application patients achieved significantly greater improvement than single-application patients on NPRS (p = 0.003) and greater improvement than double-application patients on WOMAC Pain (p = 0.009). Zero adverse events were reported across the full 31-patient cohort.
As with any observational repository data, findings reflect patient-reported outcomes in a real-world clinical setting and should be interpreted in light of the study’s stated limitations: a small sample size, no control arm, provider-determined reapplication timing, no follow-up imaging, and a WOMAC instrument validated primarily for lower extremity function. Additional applications were assigned on the basis of severity rather than protocol. The results do not establish causation.
Tissue Rationale
Paraspinal muscle ECM is composed primarily of type I collagen, and the cervical entheses are largely fibrocartilaginous, organized in zones containing collagen types I, II, III, and X. UCT shares a comparable collagen profile (types I, II, III, IV, V, VI, XII, and XIV) along with hyaluronic acid, glycosaminoglycans, and proteoglycans. Both tissues rely on that collagenous framework to distribute and dissipate tensile load, supporting homologous use of UCT as a structural matrix supplement at the site of degeneration.